Saturday, March 29, 2025 11:59:25 AM
In my view, acquiring the Roswell commercial license may be just as significant as the UCLA DCVax-L license…
The two most relevant aspects of NWBO’s prospective value are:
⭐️ Combos with other agents that are already commercialized worldwide. (For one example, consider how the global commercial success of PD-1 blockade technology may impact dendritic cell platforms!) 🤔
⭐️ Multiple Patent-Fortified DC Platforms
Moffitt has interesting connections to Roswell and the two are collaborating on at least one active clinical trial today. At a minimum, Moffitt’s work has provided solid proof of concept for the value/need for DC technology in oncology, and I think we may soon learn more about the relationship between Moffitt and Roswell in the context of NWBO.
It is great to see the collaborative/cooperative efforts that have advanced DC technology from the Steinman era into a new era of combo therapies. NCI-designated cancer centers and multiple government agencies have worked together in developing dendritic cell-based platform technologies, which are now beginning to demonstrate efficacy in combo with established therapies that are already successful in the expanding global immunotherapy market.
Just a week after giving birth, Dallas Carroll was diagnosed with stage 4 breast cancer. Now, an experimental dendritic cell vaccine is giving her a shot at a cure—proof that innovative treatments are saving lives.
— Moffitt Cancer Center (@MoffittNews) March 5, 2025
Read her full story: https://t.co/Hwq0iigidQ#MoffittImpact pic.twitter.com/tKUQWyVUcm
Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. https://t.co/QgI6ZQfgtq pic.twitter.com/kLMjIDjwXj
— JAMA Oncology (@JAMAOnc) December 5, 2024
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
